Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Homology Medicines, Inc. (not Q32 Bio Inc.) on June 15, 2022. The filing details the voting results for director elections and the ratification of the independent auditor. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol FIXX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
A total of 48,696,845 shares were present or represented by proxy, representing approximately 84.85% of outstanding common stock as of the April 18, 2022 record date. The following proposals were approved:
- Item 1: Election of Class I Directors
- Jeffrey V. Poulton: Elected with 34,128,578 votes FOR, 4,032,293 votes WITHHELD, and 10,535,974 Broker Non-Votes.
- Alise S. Reicin, M.D.: Elected with 33,811,623 votes FOR, 4,349,248 votes WITHHELD, and 10,535,974 Broker Non-Votes.
- Item 2: Ratification of Independent Auditor
- Deloitte & Touche LLP was ratified for the year ending December 31, 2022.
- Votes FOR: 48,122,966
- Votes AGAINST: 421,138
- Votes ABSTAINED: 152,741
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the correct registrant name is Homology Medicines, Inc. (FIXX), not Q32 Bio Inc.
- Confirm the tenure of the newly elected Class I Directors (Jeffrey V. Poulton and Alise S. Reicin, M.D.) extends until the 2025 Annual Meeting.
- Note the significant number of Broker Non-Votes (10,535,974) on the director election proposals.
- Review the definitive proxy statement filed on April 29, 2022, for detailed background on the nominees and auditor appointment.